SC 13G/A: UroGen Pharma Ltd.

AI Summary

SC 13G/A filing by UroGen Pharma Ltd..

Risk Assessment

Risk Level: low

Filing Documents

• greatpoint-urgn123123a1.htm (SC 13G/A) — 109KB
• 0001172661-24-001527.txt ( ) — 110KB

(a)Name of Issuer

Item 1. (a)Name of Issuer UROGEN PHARMA LTD.

(b)Address of Issuer’s Principal

Item 1. (b)Address of Issuer’s Principal Executive Offices 400 Alexander Park Drive Princeton, New Jersey 08540

(a)Names of Persons Filing

Item 2. (a)Names of Persons Filing: Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D. Mr. Ortav Yehudai The Reporting Persons have entered into a Joint Filing Agreement, dated February 14, 2024, a copy of which is filed with this SCHEDULE 13G/A as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

(b)Address

Item 2. (b)Address of Principal Business Office: The address of the principal business office of each of the Reporting Persons is 165 Mason Street, 3rd Floor Greenwich, CT 06830

(c)Citizenship

Item 2. (c)Citizenship: Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. Ortav Yehudai is a citizen of the United States.

(d)Title of Class of Securities

Item 2. (d)Title of Class of Securities Ordinary Shares, par value NIS 0.01 per share (the “Ordinary Shares”)

(e) CUSIP No

Item 2. (e) CUSIP No.: M96088105 CUSIP No. M96088105 SCHEDULE 13G/A Page 6 of 9 Pages

If

Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: CUSIP No. M96088105 SCHEDULE 13G/A Page 7 of 9 Pages Item 4.Ownership Biomedical Value Fund, L.P. (“BVF”) is the record owner of 1,467,505 shares (the “BVF Shares”). Great Point Partners, LLC (“Great Point”) is the investment manager of BVF, and by virtue of such status may be deemed to be the beneficial owner of the BVF Shares. Each of Dr. Jeffrey R. Jay, M.D. (“Dr. Jay”), as Senior Managing Member of Great Point, and Mr. Ortav Yehudai (“Mr. Yehudai”), as Managing Director of Great Point, has voting and investment power with respect to the BVF Shares, an